资料显示，中牧实业股份有限公司位于北京市丰台区南四环西路188号八区16-19号楼，成立日期1998年 12月25日，上市日期1999年1月7日，公司主营业务涉及动物保健品,包括畜禽用疫苗、诊断液、兽药等 几大类。动物营养品:包括饲料原料、饲料添加剂、预混合饲料及大宗饲料原料的进出口贸易。主营业 务收入构成为：化药35.78%，贸易27.87%，饲料19.21%，生物制品16.10%，其他1.04%。 中牧股份所属申万行业为：农林牧渔-动物保健Ⅱ-动物保健Ⅲ。所属概念板块包括：禽流感药物、兽 药、年报预增、宠物经济、病毒防治等。 2月24日，中牧股份盘中上涨2.09%，截至13:43，报7.83元/股，成交6372.50万元，换手率0.80%，总市 值79.96亿元。 资金流向方面，主力资金净流入208.71万元，特大单买入755.45万元，占比11.85%，卖出151.59万元， 占比2.38%；大单买入1138.46万元，占比17.87%，卖出1533.62万元，占比24.07%。 中牧股份今年以来股价跌0.51%，近5个交易日跌1.26%，近20日跌7.77%，近60日跌0.13%。 机构持仓方面，截止 ...

Core Viewpoint - Zhongmu Co., Ltd. experienced a stock price increase of 5.72% on January 19, reaching 8.32 CNY per share, with a trading volume of 124 million CNY and a turnover rate of 1.49%, resulting in a total market capitalization of 8.496 billion CNY [1] Company Overview - Zhongmu Co., Ltd. is located at No. 188, West Fourth Ring South Road, Fengtai District, Beijing, and was established on December 25, 1998, with its listing date on January 7, 1999 [1] - The company's main business involves animal health products, including vaccines, diagnostic liquids, and veterinary drugs, as well as animal nutrition products such as feed raw materials, feed additives, and premixed feeds [1] - The revenue composition of the main business is as follows: chemical drugs 35.78%, trade 27.87%, feed 19.21%, biological products 16.10%, and others 1.04% [1] Shareholder Information - Among the top ten circulating shareholders of Zhongmu Co., Ltd., a fund under Southern Fund holds a position. The Southern CSI 1000 ETF (512100) reduced its holdings by 74,000 shares in the third quarter, now holding 4.6728 million shares, which accounts for 0.46% of the circulating shares [2] - The Southern CSI 1000 ETF (512100) was established on September 29, 2016, with a current scale of 76.63 billion CNY. Year-to-date returns are 8.41%, ranking 1574 out of 5579 in its category; over the past year, returns are 43.88%, ranking 1725 out of 4225; and since inception, returns are 23.98% [2] - The fund manager of Southern CSI 1000 ETF (512100) is Cui Lei, who has a cumulative tenure of 7 years and 75 days, managing total fund assets of 122.76 billion CNY, with the best fund return during the tenure being 247.63% and the worst being -15.93% [2]

Core Viewpoint - Zhongmu Co., Ltd. has shown a positive stock performance with an 18.29% increase year-to-date and a significant rise in net profit for the first nine months of 2025, indicating strong operational growth in the animal health sector [1][2]. Financial Performance - As of September 30, 2025, Zhongmu Co., Ltd. achieved a revenue of 4.442 billion yuan, representing a year-on-year growth of 6.32% [2]. - The net profit attributable to shareholders reached 225 million yuan, marking a substantial increase of 175.49% compared to the previous year [2]. Stock Market Activity - On November 10, 2025, Zhongmu's stock price rose by 2.06% to 7.91 yuan per share, with a trading volume of 71.25 million yuan and a turnover rate of 0.89% [1]. - The company has a total market capitalization of 8.077 billion yuan [1]. Shareholder Information - As of September 30, 2025, the number of shareholders decreased by 6.45% to 36,900, while the average number of circulating shares per person increased by 6.90% to 27,706 shares [2][3]. - The top ten circulating shareholders include significant institutional investors, with notable changes in holdings among major ETFs [3]. Business Overview - Zhongmu Co., Ltd. specializes in animal health products, including vaccines, diagnostic liquids, and veterinary drugs, with a revenue composition of 35.78% from chemical drugs, 27.87% from trade, 19.21% from feed, and 16.10% from biological products [1]. - The company is categorized under the agricultural and animal health sectors, with involvement in various concepts such as small-cap stocks and rural revitalization [1].

Core Viewpoint - Zhongmu Co., Ltd. is a leading enterprise in the domestic animal health industry, focusing on animal health products and nutrition, with a differentiated competitive advantage across the entire industry chain [1] Group 1: Business Performance - In Q3 2025, Zhongmu's revenue reached 4.442 billion, ranking first among 14 companies in the industry, significantly higher than the second-ranked Reap Bio's 2.544 billion [2] - The main business composition includes: chemical drugs 999 million (35.78%), trade 778 million (27.87%), feed 536 million (19.21%), biological products 450 million (16.10%), and others 28.92 million (1.04%) [2] - The net profit for the same period was 230 million, ranking third in the industry, with Reap Bio at 391 million and KQ Bio at 337 million [2] Group 2: Financial Ratios - As of Q3 2025, Zhongmu's debt-to-asset ratio was 28.26%, slightly lower than the previous year's 27.77% and below the industry average of 28.36%, indicating good solvency [3] - The gross profit margin for the same period was 17.07%, slightly down from 17.23% year-on-year, and significantly lower than the industry average of 40.13%, suggesting a need for improvement in profitability [3] Group 3: Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 6.45% to 36,900, while the average number of circulating A-shares held per household increased by 6.90% to 27,700 [5] - Among the top ten circulating shareholders, Guotai Junan CSI Livestock Breeding ETF ranked third with 11.296 million shares, an increase of 4.0293 million shares from the previous period [5] Group 4: Management Compensation - The chairman, Wu Dongxun, saw his salary decrease from 1.545 million in 2023 to 663,000 in 2024, a reduction of 882,000 [4] - The general manager, Li Yin, has a salary of 187,000 for 2024 [4] Group 5: Future Outlook - Analysts expect Zhongmu's revenue and net profit to grow year-on-year in the first half of 2025, driven by the chemical drug segment and improved cost control [5] - Business highlights include potential improvements in livestock health business due to favorable breeding cycles and new business developments in pet health and food brands [5] - Southwest Securities projects EPS for 2025-2027 to be 0.28, 0.34, and 0.38, with a target price of 8.96 based on a 32x PE for 2025 [6]